Skip to content
DataLookout
Menu

PACERNCT07774455

Pacritinib Effectiveness in Real-world Settings

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved 42 days later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 9 words
    • Primary endpoints: details revised at 6 of 49 entries
    • Primary and study completion pushed from Jan 27, 2027 to Mar 10, 2027
    • Study sites: 3 to 5
  2. Notable Recruitment opened
    • Trial sites expanded: 0 → 3 locations
    • Start date changed from estimate of Aug 1, 2026 to Aug 13, 2026
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

≥50% spleen length reduction
Timeframe: From the Index Date to Week 24 or best response in spleen reduction, assessed up to 49 months.
≥20% spleen length reduction
Timeframe: From the Index Date to Week 24 or best response in spleen reduction, assessed up to 49 months.
Change in spleen length
Timeframe: Index to Week 24 and at other timepoints, assessed up to 49 months.
Improvement in spleen size category
Timeframe: Index to Week 24 and at other timepoints, assessed up to 49 months.
Among those with ≥1 MF-related symptom at index Symptom-specific resolution
Timeframe: Index to Week 24 and at other timepoints, assessed up to 49 months.
Among those with ≥1 MF-related symptom at index Decrease in total number of MF-symptoms
Timeframe: Index to Week 24 and at other timepoints, assessed up to 49 months.
Among those with ≥1 MF-related symptom at index Change in total number of MF-symptoms
Timeframe: Index to Week 24 and at other timepoints, assessed up to 49 months.
Change in blood counts (i.e., white blood cells [WBC], platelets, absolute neutrophil counts, peripheral blast percentage)
Timeframe: Index to Week 24 and at other timepoints, assessed up to 49 months.
Among those who are non-transfusion independent (TI) (≥1 RBC transfusion in prior 12 weeks) at index RBC-TI - absence of RBC transfusions over any 12-week period
Timeframe: Index to Week 24 and at other timepoints, assessed up to 49 months.
Among those who are non-transfusion independent (TI) (≥1 RBC transfusion in prior 12 weeks) at index ≥50% reduction in number of RBC units transfused
Timeframe: Index to Week 12 & Index to Week 24
Among those who are non-transfusion independent (TI) (≥1 RBC transfusion in prior 12 weeks) at index ≥50% reduction in monthly rate of RBC units transfused
Timeframe: Index to Week 12 & Index to Week 24
Among those who are non-transfusion independent (TI) (≥1 RBC transfusion in prior 12 weeks) at index change in the number of RBC units transfused
Timeframe: Index to Week 24
Among those who are non-transfusion independent (TI) (≥1 RBC transfusion in prior 12 weeks) at index change in the monthly rate of RBC units transfused
Timeframe: Index to Week 24
Among those with a platelet count <100 x 109/L at index date Absolute increase in platelet counts ≥30 x 109/L without a platelet transfusion in the prior 2 days
Timeframe: Index to best response, assessed up to 49 months.
Among patients with Hb <10 g/dL at index and who are RBC-transfusion dependent (TD) (≥3 RBC units transfused in prior 12 weeks) at index: achieved RBC-TI
Timeframe: 12-Week Period with no RBC transfusions administered during the period
Among patients with Hb <10 g/dL at index and who are not RBC-transfusion dependent (TD) (≥3 RBC units transfused in prior 12 weeks) at index: ≥1.5 g/dL increase in average Hb
Timeframe: 12-Week Period with no RBC transfusions administered during the period
Among patients who have IWG Hb Minor Response at index and are RBC-TD at index ≥50% reduction in RBC transfusion
Timeframe: 12-Week Period without being fully RBC-TI
Among patients who have IWG Hb Minor Response at index and are not RBC-TD at index ≥1 g/dL increase in average Hb
Timeframe: 12-Week Period without being fully RBC-TI
Physician-reported progression to leukemia (AML)
Timeframe: Index to Follow-up, assessed up to 49 months.
Overall survival
Timeframe: Index to Follow-up, assessed up to 49 months.
Leukemia-free Survival
Timeframe: Index to Follow-up, assessed up to 49 months.
Type, dose, and number of MF-directed therapies administered
Timeframe: At Index (Baseline)
Reasons for treatment switch from a prior MF-directed therapy to pacritinib
Timeframe: At Index (Baseline)
Method used to switch from prior JAKi to pacritinib
Timeframe: At Index (Baseline)
Physician reported (or Physician confirmed) JAKi withdrawal syndrome after switching to pacritinib from a different JAKi
Timeframe: Prior to (index date) and after initiation of pacritinib (up to 49 months).
Pacritinib line of therapy, treatment dose and frequency, changes in dose/and or frequency, frequency of dose changes and reasons for change
Timeframe: Prior to (index date) and after initiation of pacritinib (up to 49 months).
Duration of treatment with pacritinib
Timeframe: Prior to (index date) and after initiation of pacritinib (up to 49 months).
Concomitant MF-related medications
Timeframe: Prior to (index date) and after initiation of pacritinib (up to 49 months).
Reason for discontinuation of pacritinib
Timeframe: Prior to (index date) and after initiation of pacritinib (up to 49 months).
Subsequent MF-therapy following discontinuation of pacritinib and time to next Treatment
Timeframe: Prior to (index date) and after initiation of pacritinib (up to 49 months).
Demographic characteristics include age, sex, race/ethnicity, geographic region, and insurance type
Timeframe: At Index (Baseline)
Body mass index (BMI) for all participants enrolled
Timeframe: At Index (Baseline)
Receipt of allo-HSCT among patients referred to allo-HSCT
Timeframe: Index to Week 24
Duration of treatment with pacritinib prior to allo-HSCT
Timeframe: Index to Week 24
Dose of pacritinib prior to allo-HSCT
Timeframe: Index to Week 24
Discontinuation of pacritinib prior to allo-HSCT
Timeframe: Index to Week 24
Treatment with pacritinib during conditioning
Timeframe: Index to Week 24
Dose of pacritinib during condition
Timeframe: Index to Week 24
Duration of treatment with pacritinib after allo-HSCT
Timeframe: Index to Week 24
Dose of pacritinib after allo-HSCT
Timeframe: Index to Week 24
Type of MF for all participants enrolled
Timeframe: At Index (Baseline)
Comorbidities for all participants enrolled
Timeframe: At Index (Baseline)
MF Risk Category for all participants enrolled
Timeframe: At Index (Baseline)
Bone Marrow Fibrosis Grade for all participants enrolled
Timeframe: At Index (Baseline)
Type of MF Mutations for all participants enrolled
Timeframe: At Index (Baseline)
Variant Allele Frequency (VAF) for all participants enrolled
Timeframe: At Index (Baseline)
Number of Driver Mutations for all participants enrolled
Timeframe: At Index (Baseline)
Number of High-Risk Mutations for all participants enrolled
Timeframe: At Index (Baseline)
Karyotype for all participants enrolled
Timeframe: At Index (Baseline)

Arms and interventions

Other: Not applicable- observational study

Sites

5 sites in 1 country